At the time of inclusion seven out of nine patients received cytoreductive treatments for MPN: these treatments included IFN-α (N=5, Pegasys, 4 patients received 45 ugx1sc/week, 1 patient received 135 ug x 1 sc/every fourth week), ANA (N=1), and phlebotomy (N=1). This evidence concerns the gene BTG3 and myeloproliferative disorder.